Picture of Trans Lux logo

TNLX — Trans Lux News Story

0.000.00%
us flag iconLast trade - 00:00
TechnologyHighly SpeculativeMicro Cap

Jefferies raises PT on Australia's Telix Pharmaceuticals on upbeat U.S. sales

** Jefferies raises PT on Telix Pharmaceuticals  TLX.AX  to
A$13.30 from A$13.00 on ongoing U.S. sales growth of Illuccix
product
    ** The cancer-focused pharma co on Tuesday posted a
multi-fold jump in FY revenue to A$160.1 mln ($107.64 mln) from
last year's A$7.6 mln
    ** However, Telix logged a net loss after tax of A$104.1
mln, versus with a profit of A$80.5 mln due to investment to
scale-up commercial and clinical activities
    ** Jefferies says growth can continue and hikes FY23 U.S.
Illuccix gross margin sales
    ** Broker says emerging clinical practice in the United
States that includes multiple PET scans bodes well for TLX's
sales growth 
    ** All of the six analysts rate stock "buy" or higher; their
median PT is A$9.29 - Refinitiv data
    ** YTD, Telix stock down ~4%

    ($1 = 1.4874 Australian dollars)

 (Reporting by Savyata Mishra in Bengaluru)
 ((Savyata.Mishra@thomsonreuters.com))

Recent news on Trans Lux

See all news